CURX

CURANEX PHARMACEUTICALS INC

5.31

+0.55+11.55%

After Hours: 5.43 +0.12 +2.26%19:30 10/09 EDT

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE4.610/4.760

TODAY RANGE4.610-5.31

VOL17.09K

MARKET CAP8.33M

52 WEEK RANGE3.576-16.93

AVG VOL (3M)20.25K

% TURNOVER0.98%

TURNOVER--

P/E (TTM)-0.7123

% RANGE14.71%

EPS(TTM)-7.4550

P/E(FORWARD)--

P/B1.573

BVPS3.376

DIVIDEND--

P/S--

BETA--

DIV YIELD0.00%

FREE FLOAT MKT CAP3.22M

SHARES OUTSTANDING1.57M

NEXT EARNINGS--

FREE FLOAT606.07K

LOT SIZE1

EX-DATE08/20/2026

News

Press Releases

Financial Reports

Profile

TipRanks·09/04 21:31
Curanex Pharmaceuticals Regains Nasdaq Compliance After Reverse Split
TipRanks·08/19 23:50
Curanex Pharmaceuticals Inc trading halted, news pending
TipRanks·08/17 21:18
Curanex Announces Reverse Stock Split to Maintain Nasdaq Listing
Benzinga·08/05 12:05
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga·07/29 12:05
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga·07/22 12:05
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga·06/30 12:05
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga·06/29 21:05
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga·06/09 21:06
12 Health Care Stocks Moving In Tuesday's After-Market Session
PR Newswire·05/22 11:39
Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)
PR Newswire·05/18 11:37
Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)
TipRanks·05/14 13:54
Curanex Advances Phyto-N Program and Expands Indications
Benzinga·05/14 13:05
Curanex Pharmaceuticals Q1 EPS $(0.11) Down From $(0.01) YoY
Benzinga·05/14 12:56
Curanex Continues To Advance Phyto-N As Lead Development Candidate, With Ulcerative Colitis As Initial Target Indication; Co. Prepares Phyto-N For Planned IND Submission In Q4 Of 2026
PR Newswire·05/12 22:08
Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)

Same Industry

Name/Symbol

Change%

Price

REGN

GridAI Tech

GRDX

+3.54%

4.970

BNTX

UTHR

VRTX

SIGA

Moderna

MRNA

+14.21%

225.00

CRL

MEDP

TLPH

ICLR

CBPO

IQV

MOLN

Arcturus Therape

ARCT

+6.76%

13.74

GILD

PRA Health

PRAH

0.00%

165.21

INCY

Aptevo Therapeutics Inc

APVO

-0.56%

1.790

Biospecifics

BSTC

+0.15%

88.53

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.